Memorial Sloan Kettering Cancer Center @MSKCancerCenter · 03 Sep 2026
🚨 New research published in @NEJM shows daraxonrasib is showing early but strong signs it could be effective against lung cancer. In a phase 1/2 clinical trial led by MSK thoracic medical oncologist @KCArbourMD, more than 30% of patients with previously treated metastatic https://t.co/W1acZmYKFn
1 021Views
14Likes
0Reposts
2Replies
2Quotes
0Bookmarks
Is that a lot?
0.45×vs this author's median2 254 views is typical
33Percentile for this authorof 6 recent posts
0.17×vs 100K–1M median6 178 views is typical
0.98%Reachviews ÷ followers
1.76%Engagement rateof viewers reacted